^
Association details:
| Biomarker: | EGFR mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | irinotecan (Topoisomerase I inhibitor) + Teysuno (gimeracil/oteracil/tegafur) (Thymidylate synthase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Phase II study of S-1 and irinotecan combination therapy in EGFR-mutated non-small cell lung cancer resistant to epidermal growth factor receptor tyrosine kinase inhibitor: North Japan Lung Cancer Study Group Trial 0804 (NJLCG0804)
Published date:
08/16/2022
Excerpt:
We conducted a multicenter phase II trial to evaluate the efficacy and safety of S-1 and irinotecan combination therapy in patients with epidermal growth factor receptor-mutated non-small-cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors....Progression-free survival and overall survival were 5.0 and 17.1 months, respectively. The overall response rate was 52.0%.
DOI:
https://doi.org/10.1007/s12032-022-01755-3
